Research graph
References from Effects of current therapeutic interventions on insulin resistance. Local targets link to admitted publications; unresolved targets remain external evidence.
10.2337/diab.37.6.667
10.2337/diab.37.6.667 · External reference
UK Prospective Diabetes Study 33: Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
1998 · External reference
Promising new approaches.
1999 · External reference
10.2337/diabetes.31.5.382
10.2337/diabetes.31.5.382 · External reference
Therapy for type 2 diabetes mellitus.
1998 · External reference
Unresolved reference
1994 · External reference
10.1007/bf00579720
10.1007/bf00579720 · External reference
10.2337/diacare.15.6.737
10.2337/diacare.15.6.737 · External reference
10.2165/00002512-199813020-00008
10.2165/00002512-199813020-00008 · External reference
Gaal LF, Van Acker KL, De Damsbo P, Leeuw IH. Metabolic effects of repaglinide, a new oral hypoglycemic agent in therapy‐naive type 2 diabetes (Abstract).
1995 · External reference
Repaglinide. a novel, short‐acting hypoglycemic agent for type 2 diabetes mellitus.
10.1002/j.1875-9114.1998.tb03137.x · 1998 · External reference
Pathophysiology of insulin resistance in human disease.
1997 · External reference
10.1136/pgmj.72.853.657
10.1136/pgmj.72.853.657 · External reference
10.1002/(sici)1096-9136(1998120)15:4<s28::aid-dia748>3.3.co;2-k
10.1002/(sici)1096-9136(1998120)15:4<s28::aid-dia748>3.3.co;2-k · External reference
for the Repaglinide Study Group. Repaglinide. a novel oral hypoglycemic agent in type 2 diabetes: a randomized, placebo‐controlled, double blind, fixed‐dose study.
1998 · External reference
for the Repaglinide Study Group. Multicenter. randomized comparison of therapeutic effects of long‐term use of repaglide with glyburide in type 2 diabetes.
1998 · External reference
10.2337/diacare.21.11.1897
10.2337/diacare.21.11.1897 · External reference
UK Prospective Diabetes Study 34: Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes.
1998 · External reference
10.1056/nejm199803263381303
10.1056/nejm199803263381303 · External reference
Metformin. a safe and effective treatment in the management of NIDDM.
1997 · External reference
10.1016/s0950-351x(88)80043-0
10.1016/s0950-351x(88)80043-0 · External reference
10.1111/j.1464-5491.1995.tb00410.x
10.1111/j.1464-5491.1995.tb00410.x · External reference
Obesity. an escalating problem.
1997 · External reference
The insulin sparing action of troglitazone in intensively treated NIDDM patients exceeds that of metformin.
1998 · External reference
10.1056/nejm199508313330902
10.1056/nejm199508313330902 · External reference
10.1016/s0149-2918(98)80132-x
10.1016/s0149-2918(98)80132-x · External reference
UK Prospective Diabetes Study 24: Relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non‐insulin dependent diabetes with primary diet failure followed for six years.
1998 · External reference
10.2337/diacare.21.5.701
10.2337/diacare.21.5.701 · External reference
Metformin. a review of its pharmacological properties and therapeutic use.
1979 · External reference
10.1016/s0149-2918(96)80017-8
10.1016/s0149-2918(96)80017-8 · External reference
Unresolved reference
1996 · External reference
10.7326/0003-4819-121-12-199412150-00004
10.7326/0003-4819-121-12-199412150-00004 · External reference
10.2337/diacare.20.10.1512
10.2337/diacare.20.10.1512 · External reference
Insulin resistance: its role in health and disease and implications for nutritional management.
1997 · External reference
Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
10.1001/jama.1997.03550200039029 · 1997 · External reference
10.2165/00002018-199512010-00003
10.2165/00002018-199512010-00003 · External reference
Unresolved reference
1992 · External reference
10.1172/jci112389
10.1172/jci112389 · External reference
Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin‐dependent diabetes mellitus.
1983 · External reference
10.2165/00003495-198122030-00003
10.2165/00003495-198122030-00003 · External reference
Oral hypoglycemic agents.
1989 · External reference
A new oral therapy for diabetes management: alpha‐glucosidase inhibition with acarbose.
1995 · External reference
10.2337/diacare.13.12.1240
10.2337/diacare.13.12.1240 · External reference
10.1016/s0889-8529(18)30395-5
10.1016/s0889-8529(18)30395-5 · External reference
10.2337/diacare.21.1.s32
10.2337/diacare.21.1.s32 · External reference
10.1016/s0002-9343(99)80343-x
10.1016/s0002-9343(99)80343-x · External reference
10.2337/diacare.17.10.1100
10.2337/diacare.17.10.1100 · External reference
10.1016/s0140-6736(94)90822-2
10.1016/s0140-6736(94)90822-2 · External reference
10.1016/0002-9343(81)90773-7
10.1016/0002-9343(81)90773-7 · External reference
Type 2 diabetes: glycemic targets and oral therapies for older patients.
1998 · External reference
The pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus.
1998 · External reference
10.1007/bf00315490
10.1007/bf00315490 · External reference
Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing.
1997 · External reference
Mechanism of metformin action in obese and lean NIDDM subjects.
1993 · External reference
10.1056/nejm199508313330903
10.1056/nejm199508313330903 · External reference
UK Prospective Diabetes Study UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non‐insulin dependent diabetes followed for three years.
1995 · External reference
10.2337/diacare.15.6.755
10.2337/diacare.15.6.755 · External reference
10.1016/0306-3623(93)90411-p
10.1016/0306-3623(93)90411-p · External reference
10.1016/s0002-9343(97)00254-4
10.1016/s0002-9343(97)00254-4 · External reference
Long‐term efficacy and safety of acarbose in the treatment of obese subjects with non‐insulin‐dependent diabetes mellitus.
10.1001/archinte.1994.00420210080009 · 1994 · External reference
10.2337/diacare.14.8.732
10.2337/diacare.14.8.732 · External reference
10.2337/diacare.20.5.687
10.2337/diacare.20.5.687 · External reference
Unresolved reference
1996 · External reference
Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
10.1001/archinte.1997.00440370028004 · 1997 · External reference
Insulin therapy in obese, non‐insulin‐dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.
10.2337/diab.33.7.634 · 1984 · External reference
Unresolved reference
1994 · External reference
Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
10.2337/diab.45.12.1661 · 1996 · External reference
10.2337/diacare.13.12.1209
10.2337/diacare.13.12.1209 · External reference
10.2337/diacare.18.6.775
10.2337/diacare.18.6.775 · External reference
10.1001/archfami.7.2.155
10.1001/archfami.7.2.155 · External reference
